HbInductionbyHistoneDeacetylaseInhibitor
inhibitorsdeterminethehyperacetylationofe-aminogroupsoflysineresiduesofhistones,andthismodi cationinturnleadstoareducedinteractionbetweencorehistoneproteinsandDNAinthepromoterregionofcertaingenesdetermin-ingtheirtranscriptionalactivation(Atweh&Loukopoulos,2001).However,othermechanismsnotdirectlyinvolvingmodi cationatthelevelofHBG1/2promotersmayoccur.Apicidin,apotentHDACinhibitor,hasbeendescribedtomodulatethep38MAPKpathwayinvolvedinerythropoie-tin-inducederythroiddifferentiation(Wittetal,2003;Testa,2009).Moreover,HDACs,mainlyHDAC1andHDAC2,arecomponentsofthetranscriptionalrepressioncomplexSIN3-HDAC-NuRD-BCL11A,sothatthepharmacologicaldown-regulationofBCL11AcouldresultintheinductionofHBG1/2expression(Bradneretal,2010;Bauer&Orkin,2011;Sankaran,2011).
Histonedeacetylasesarerecruitedbyandinteractwithavari-etyoftranscriptionalfactorsinvolvedinglobingeneregulation,sothatHDACinhibitorscouldmodulateglobingeneexpressionindirectlythroughtheregulationoftherecruitmentofcoactiva-torandcorepressorcomplexes.HowtheinterplaybetweenHDACsandtranscriptionalfactorsandcofactorsexertitseffectsonglobinchromatinandresultintranscriptionalsilencingoractivationoftheglobingenesisstillunclear.FurtherstudiesareneededtounderstandtheexactmechanismsofactionofGVSandtoinvestigateallthegeneswhoseexpressionismodulatedbyGVS.Thisisofparticularimportance,asoneofthemajorlimitationstotheuseofHDACinhibitorsinvivoisthewidevarietyofrolesplayedbythesecompoundsinanumberoftis-sues,sothattoxicitycouldbeamajorproblembeforeHb-inductiveeffectsareseen(Sankaran,2011).
Asmentionedearlier,GVShasagoodsafetypro lewhengiventooncologicalpatients.AdverseeventsinducedbyHDACinhibitorsaregenerallywellmanagedinsuchpatients,however,chronicadministrationofthesecom-poundsmayrepresentaprobleminnon-oncologicalpathol-ogies,suchasSCDandb-thalassaemia.OurinvitrodatausingGVSasapossibleinducerofHBG1/2indicatethatthecompoundisactiveatconcentrationsaslowas1nmol/l.Thisconcentrationisreadlyachievableinvivoinhumansfol-lowingadministrationofalowdosageofGVS.Infact,afterasingleoraladministrationof50mgofGVS,theplasmalevelpersistsabovethisconcentrationforatleast8–10h(Furlanetal,2011)suggestingthatevenalowerdosecouldbeadministeredtomaintainthisconcentration.
Inasmalltrialinsystemic-onsetjuvenileidiopathicarthri-tis,children(meanage,11Á6years)weretreatedwithGVSat
adoseof1Á5mg/kg/d(0Á75mg/kgat12-hintervals)for12weeks.Thedrugshowedagoodsafetypro lewithmildadverseevents,whichwerereversibleandofshortduration(Vojinovic&Damjanov,2011).Assessmentofsafetywastheprimaryendpointofthetrialbuttheauthorsalsoreportedsignsofef cacy,asjudgedbyAmericanCollegeofRheuma-tology(ACR)Pediatric(ACRPedi)30,ACRPedi50andACRPedi70improvementaswellasimprovementsinmobilityandwell-beingofthepatients.Furthermore,toourknowledge,GVSiscurrentlytheonlyHDACinhibitorallowedtobeadministeredtochildren.
LiteraturedatashowthatlowdosesofHDACinhibitorshavevariouspharmacologicalactivitiesmeasuredinnormalcellswithoutshowingtoxiceffects(Furlanetal,2011;Vojinovic&Damjanov,2011).Thelatteraresometimesobservedatgreaterdosesneededtoachieveananti-tumoureffect,thuslimitingthetherapeuticwindowofsomeHDACinhibitors.TheexploitationofthepharmacologicalactivityexertedbyHDACinhibitorsatlow,non-antitumourconcen-trationsisstillinitsinfancy,butitdeservesamoreaccurateandwidespreadexamination.ClinicalexperiencewithGVSsuggeststhatlowdoseofthisdrugcouldbeadministeredwithoutserioussideeffects.
Notwithstandingthelimitationdiscussedabove,ourresultssuggestthatGVSisamoleculeworthyoffurtherinvestigationasanHbinducer.Tobetterevaluatethepossi-bleinvivouseofthemolecule,studieswithmurinemodelsofSCD/b-thalassaemiaarerequired.Inaddition,otherdis-easesassociatedwithineffectiveerythropoiesis,suchascon-genitaldyserythropoieticanaemias,couldbeanotherpossibletherapeutictargetofGVSaswellasnovelHDACinhibitors.
Acknowledgements
L.R.:designedtheresearchstudy,performedtheinvitroexperiments,analysedthedataandwrotethepaper;L.S.:performedtheresearch,contributedtodataanalysisanddraftingofthemanuscript;G.F.:designedtheresearchstudy,analysedthedataandwrotethepaper;D.M:performedtheresearch,contributedtodataanalysis;E.T:performedthecyto uorimetricexperiments;L.P.:performedthecyto uori-metricexperimentsandcontributedtodataanalysis;M.D.C.:designedtheresearchstudy,contributedtodataanalysisandsupervisedthemanuscript.ThisstudywassupportedbyItal-farmaco,S.p.A.GFandDMareemployeesofItalfarmaco,whichproducesGivinostat/ITF2357.Theotherauthorsdeclarenocompeting nancialinterests.
References
Akinsheye,I.,Alsultan,A.,Solovieff,N.,Ngo,D.,Baldwin,C.T.,Sebastiani,P.,Chui,D.H.K.&Steinberg,M.H.(2011)Fetalhemoglobininsicklecellanemia.Blood,118,19–27.
Atweh,G.F.&Fathallah,H.(2010)Pharmacologicinductionoffetalhemoglobinproduction.Hematology/OncologyClinicsofNorthAmerica,24,1131–1144.
Atweh,G.F.&Loukopoulos,D.(2001)Pharmaco-logicalinductionoffetalhemoglobininsicklecelldiseaseandbeta-thalassemia.SeminarsinHematology,38,367–373.
Bakanay,S.M.,Dainer,E.,Clair,B.,Adekile,A.,Daitch,L.,Wells,L.,Holley,L.,Smith,D.&Kutlar,A.(2005)Mortalityinsicklecellpatientsonhydroxyureatherapy.Blood,105,545–547.
ª2014JohnWiley&SonsLtd,BritishJournalofHaematology7
2014 TO P Modulation o... 暂无评价 8页 免费...Histone deacetylase inhibitors are potent inducers ...Regulation of gene expression occurs also via ...
Leukemia Stem Cells by Histone Deacetylase...modulation of the acetylation status of nonhistone ...We also observed reduced expression of genes with...
Histone deacetylase inhibitor (HDI) treatment upregulates the expression of the...to HDI treatment, although the particular genes that are up- and ...
Histone deacetylase inhibitor prevents cell growth ... 318 genes were deregulated: 250 genes were ...to access global gene expression modulation upon ...
Synergy of DNA methylation and histone deacetylase inhibitors in the re-expression of RASSFIA an_专业资料。Snryo yeg fDNA ehai dhitedaeyls mtyltonan son ...
Synergy of DNA methylation and histone deacetylase inhibitors in the re-expression of RASSFIA an_专业资料。Snryo yeg fDNA ehai dhitedaeyls mtyltonan son ...
热门文档